Researchers in the lab of Cancer Center at Illinois (CCIL) member Xing Wang have discovered the influential role of ...

Aptamer Group plc, the developer of novel Optimer ® binders to enable innovation in the life sciences industry, announces that it has opened its new facilities in York Science Park, UK, that will ...

Aptamer Group has announced a new research programme supported by the Gates Foundation which will aim to use the firm's ...

Aptamer Group (LSE:APTA) has begun a funded research collaboration with Imperial College London aimed at adapting its ...

The licensed Optimer ® functions as a reversible, temperature-dependent inhibitor in hot-start DNA amplification protocols. The synthetic binder maintains DNA polymerase in an inactive state at ...

Generating specific cell lineages from induced pluripotent stem cells and embryonic stem cells is the holy grail of regenerative medicine. Guiding iPSCs toward a target cell line has garnered much ...

UK firm links with up global drug firms to make synthetic antibodies capable of binding to targets such as tumour cells Inside a science park lab next to the University of York, two clusters of robots ...

The few sensors that detect and measure molecules in the body depend on the specific chemistry of the target analyte. For example, glucose sensors quantify levels of the sugar thanks to glucose ...

Two top 10 pharma companies are seeking to trial Optimer-Fc for IHC Aptamer is currently working with one of the top three IHC companies to validate the Optimer-Fc platform IHC Optimer binders are ...